시장보고서
상품코드
1994671

메신저 리보핵산(mRNA) 및 차세대 백신 플랫폼 시장 보고서(2026년)

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Global Market Report 2026

발행일: | 리서치사: 구분자 The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

메신저 RNA(mRNA) 및 차세대 백신 플랫폼 시장 규모는 최근 급성장하고 있습니다. 2025년 396억 9,000만 달러에서 2026년에는 458억 8,000만 달러에 이르고, CAGR 15.6%로 성장할 전망입니다. 지난 몇 년간의 성장은 코로나19 백신의 획기적인 발전, 지금까지의 바이러스 벡터에 대한 연구, 세계 팬데믹 대응 프로그램, 유전체 시퀀싱의 발전, 그리고 핵산 백신의 초기 임상시험에 기인하는 것으로 보입니다.

메신저 리보핵산(mRNA) 및 차세대 백신 플랫폼 시장 규모는 향후 몇 년간 급성장이 전망되고 있습니다. 2030년에는 826억 1,000만 달러에 이르고, CAGR은 15.8%를 나타낼 전망입니다. 예측 기간 동안의 성장은 개인 맞춤형 암 백신 확대, 감염성 질환 파이프라인 확대, 플랫폼 기반 승인 가속화, 생명공학에 대한 자금 조달 증가, 치료용 백신의 사용 확대에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 자가증폭형 mRNA 플랫폼, 지질 나노입자를 통한 전달 기술 최적화, 모듈형 백신 플랫폼 설계, 병원체 표적에 대한 신속한 적응, 차세대 보조제 시스템 등이 있습니다.

맞춤형 의료에 대한 수요 증가는 향후 몇 년 동안 메신저 리보핵산(mRNA) 및 차세대 백신 플랫폼 시장의 성장을 견인할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전자 프로파일, 분자적 특성 및 특정 건강 상태에 따라 질병 예방 및 치료 전략을 개별적으로 조정하는 의료 접근법을 말합니다. 맞춤형 의료에 대한 수요 증가는 복잡하고 만성적인 질환의 유병률 증가에 의해 주도되고 있습니다. 이러한 질환의 경우, 치료의 효과와 안전성을 높이기 위해 표적화된 환자 맞춤형 치료 솔루션이 요구되고 있습니다. 메신저 RNA(mRNA) 및 차세대 백신 플랫폼은 개인의 유전적 및 질병 프로파일에 따라 맞춤화할 수 있는 신속하고 유연하며 고특이적인 백신 및 치료법을 설계할 수 있게 함으로써 정밀의료의 실현을 지원함으로써 맞춤형 의료를 뒷받침하고 있습니다. 맞춤형 의료를 지원합니다. 예를 들어, 미국 기반의 병원 및 헬스케어 단체인 Personalized Medicine Coalition에 따르면, 2024년 2월 기준 FDA는 2023년 16건의 희귀질환 환자를 위한 새로운 맞춤형 치료제를 승인했습니다. 승인했으며, 이는 2022년 6건에서 증가한 수치입니다. 따라서 개인 맞춤형 의약품에 대한 수요 증가가 메신저 리보핵산(mRNA) 및 차세대 백신 플랫폼 시장의 성장을 주도하고 있습니다.

mRNA 및 차세대 백신 플랫폼 시장에서 활동하는 기업들은 면역 지속성을 높이고, 변종 균주에 대한 대응 범위를 넓히며, 백신의 전반적인 성능을 향상시키기 위해 차세대 mRNA 기반 코로나19 백신 개발에 집중하고 있습니다. 차세대 mRNA 기반 코로나19 백신은 개선된 mRNA 엔지니어링 및 전달 기술을 활용하여 기존 및 신종 SARS-CoV-2 변종에 대해 보다 광범위하고 지속적인 방어력을 제공하고, 안전성, 안정성, 보관 편의성 및 바이러스 진화에 대한 신속한 적응성을 가능하게 합니다. 예를 들어, 2025년 6월 미국 소재 생명공학 기업 Moderna Inc.는 유행성 및 신종 SARS-CoV-2 변종에 대한 방어력을 향상시키기 위해 고안된 차세대 코로나19 백신 mNEXSPIKE를 발표했습니다. 이 백신은 최근 변이주에 의해 적응된 개량형 스파이크 단백질 항원을 도입하여 면역의 지속성과 효능을 향상시키는 것을 목표로 하고 있습니다. 이를 통해 지속적인 코로나19 예방 노력과 향후 부스터 접종 전략을 지원할 수 있습니다.

자주 묻는 질문

  • 메신저 RNA(mRNA) 및 차세대 백신 플랫폼 시장 규모는 어떻게 변화할 것으로 예상되나요?
  • 메신저 RNA(mRNA) 및 차세대 백신 플랫폼 시장의 성장은 어떤 요인에 기인하나요?
  • 맞춤형 의료의 수요 증가는 메신저 RNA(mRNA) 및 차세대 백신 플랫폼 시장에 어떤 영향을 미치나요?
  • 차세대 mRNA 기반 코로나19 백신의 개발 방향은 무엇인가요?
  • 2024년 FDA의 맞춤형 치료제 승인 현황은 어떤가요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 시장에서 주목 받는 신생 기업

제40장 주요 인수합병(M&A)

제41장 시장 잠재력이 높은 국가, 부문, 전략

제42장 부록

LSH 26.04.22

Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms denote advanced vaccine technologies that utilize genetic instructions, including mRNA, DNA, or viral vectors, to activate the body's immune system to produce protective proteins and establish immunity against diseases. These platforms facilitate faster vaccine development, high adaptability to emerging pathogens, scalable production, and enhanced immune responses compared to conventional vaccine methods.

The primary vaccine types of messenger ribonucleic acid (mRNA) and next-generation vaccine platforms include messenger ribonucleic acid vaccines, deoxyribonucleic acid (DNA) vaccines, viral vector vaccines, protein subunit vaccines, peptide vaccines, and other vaccine types. Messenger ribonucleic acid (mRNA) vaccines utilize synthetic mRNA sequences to instruct cells to produce specific antigens, thereby initiating an immune response against a target pathogen or disease. These platforms employ technologies including lipid nanoparticle (LNP) delivery, self-amplifying mRNA (saRNA), circular mRNA (circRNA), replicon or non-replicating platforms, and viral vector technologies. They are applied for disease indications including infectious diseases, oncology, rare diseases, and other medical conditions, and end users include pharmaceutical and biotechnology companies, contract research organizations (CROs), academic and research institutes, and hospitals and clinics.

Tariffs on bioprocess equipment, lipid materials, specialized enzymes, and cold chain components are influencing the mrna and next generation vaccine platforms market by increasing production and scale up costs. Platform manufacturing and delivery system segments are most affected where imported reagents and processing systems are widely used, especially in north america and europe. Higher import costs can raise vaccine development and commercialization budgets. However, tariffs are also encouraging local sourcing of raw materials and regional biomanufacturing capacity expansion. This supports domestic platform developers and regional vaccine supply chains.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market research report is one of a series of new reports from The Business Research Company that provides messenger ribonucleic acid (mrna) and next-generation vaccine platforms market statistics, including messenger ribonucleic acid (mrna) and next-generation vaccine platforms industry global market size, regional shares, competitors with a messenger ribonucleic acid (mrna) and next-generation vaccine platforms market share, detailed messenger ribonucleic acid (mrna) and next-generation vaccine platforms market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms industry. This messenger ribonucleic acid (mrna) and next-generation vaccine platforms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has grown rapidly in recent years. It will grow from $39.69 billion in 2025 to $45.88 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, early nucleic acid vaccine trials.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size is expected to see rapid growth in the next few years. It will grow to $82.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to growth of personalized cancer vaccines, expansion of infectious disease pipelines, faster platform based approvals, increased biotech funding, broader therapeutic vaccine use. Major trends in the forecast period include self amplifying mrna platforms, lipid nanoparticle delivery optimization, modular vaccine platform design, rapid pathogen target adaptation, next generation adjuvant systems.

The increasing demand for personalized medicine is anticipated to drive the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in the coming years. Personalized medicine refers to a medical approach in which disease prevention and treatment strategies are tailored based on an individual's genetic profile, molecular characteristics, and specific health conditions. The rising demand for personalized medicine is driven by the increasing prevalence of complex and chronic diseases, which require targeted and patient-specific therapeutic solutions to improve treatment efficacy and safety outcomes. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms support personalized medicine by enabling rapid, flexible, and highly specific vaccine and therapeutic designs that can be customized to individual genetic and disease profiles, supporting precision-based healthcare delivery. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

Companies operating in the mRNA and next-generation vaccine platforms market are focusing on developing next-generation mRNA-based COVID-19 vaccines to enhance immune durability, broaden variant coverage, and improve overall vaccine performance. Next-generation mRNA-based COVID-19 vaccines leverage improved mRNA engineering and delivery technologies to provide broader and more durable protection against existing and emerging SARS-CoV-2 variants and enhance safety, stability, and storage convenience while allowing rapid adaptation to viral evolution. For example, in June 2025, Moderna Inc., a US-based biotechnology company, introduced mNEXSPIKE, its next-generation COVID-19 vaccine designed to improve protection against circulating and emerging SARS-CoV-2 variants. The vaccine incorporates an updated spike protein antigen that more closely matches recent variants and aims to deliver enhanced immune durability and effectiveness, supporting ongoing COVID-19 prevention efforts and future booster strategies.

In July 2024, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, partnered with CureVac N.V. to advance next-generation mRNA vaccines and accelerate development. The partnership aims to fortify GlaxoSmithKline's vaccine pipeline by gaining strategic control over next-generation mRNA programs and expediting their development and commercialization. CureVac N.V. is a Germany-based biotechnology company specializing in next-generation messenger ribonucleic acid-based Covid and flu vaccines.

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market includes sales of messenger ribonucleic acid vaccines, lipid nanoparticle delivery systems, viral vector vaccines, protein subunit vaccines, recombinant antigen vaccines, next-generation adjuvants, synthetic ribonucleic acid constructs, stabilized messenger ribonucleic acid formulations, immune response modulators, and nucleic acid-based vaccine platforms. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses messenger ribonucleic acid (mrna) and next-generation vaccine platforms market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for messenger ribonucleic acid (mrna) and next-generation vaccine platforms ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types
  • 2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies
  • 3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications
  • 4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics
  • Subsegments:
  • 1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines
  • 2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines
  • 3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines
  • 4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines
  • 5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines
  • 6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines
  • Companies Mentioned: Pfizer Inc.; Sanofi S.A.; AstraZeneca PLC; Thermo Fisher Scientific Inc.; GSK plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company Limited; Moderna Inc.; BioNTech SE; Novavax Inc.; Walvax Biotechnology Co Ltd; Arcturus Therapeutics Inc; Gennova Biopharmaceuticals Ltd; Vaxxas Pty Ltd; Vaxart Inc; Ethris GmbH; The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited; eTheRNA Immunotherapies NV; Stemirna Therapeutics Co Ltd; Primrose Bio Inc; Acuitas Therapeutics Inc; and Incepta Vaccine Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Self Amplifying Mrna Platforms
    • 4.2.2 Lipid Nanoparticle Delivery Optimization
    • 4.2.3 Modular Vaccine Platform Design
    • 4.2.4 Rapid Pathogen Target Adaptation
    • 4.2.5 Next Generation Adjuvant Systems

5. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Analysis Of End Use Industries

  • 5.1 Pharmaceutical And Biotechnology Companies
  • 5.2 Contract Research Organizations (Cros)
  • 5.3 Academic And Research Institutes
  • 5.4 Hospitals And Clinics
  • 5.5 Government Vaccine Programs

6. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Segmentation

  • 9.1. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Messenger Ribonucleic Acid Vaccines, Deoxyribonucleic Acid (DNA) Vaccines, Viral Vector Vaccines, Protein Subunit Vaccines, Peptide Vaccines, Other Vaccine Types
  • 9.2. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Technology or Platform, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lipid Nanoparticle (LNP) Delivery, Self-Amplifying Messenger Ribonucleic Acid, Circular Messenger Ribonucleic Acid, Replicon or Non-replicating Platforms, Viral Vector Technologies
  • 9.3. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Infectious Diseases, Oncology, Rare Diseases, Other Disease Indications
  • 9.4. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutes, Hospitals and Clinics
  • 9.5. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Sub-Segmentation Of Messenger Ribonucleic Acid Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Conventional Messenger Ribonucleic Acid Vaccines, Self Amplifying Messenger Ribonucleic Acid Vaccines, Modified Messenger Ribonucleic Acid Vaccines, Circular Messenger Ribonucleic Acid Vaccines
  • 9.6. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Sub-Segmentation Of Deoxyribonucleic Acid Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Plasmid Deoxyribonucleic Acid Vaccines, Viral Assisted Deoxyribonucleic Acid Vaccines, Synthetic Deoxyribonucleic Acid Vaccines, Gene Based Deoxyribonucleic Acid Vaccines
  • 9.7. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Sub-Segmentation Of Viral Vector Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Adenovirus Based Viral Vector Vaccines, Lentivirus Based Viral Vector Vaccines, Poxvirus Based Viral Vector Vaccines, Measles Virus Based Viral Vector Vaccines
  • 9.8. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Sub-Segmentation Of Protein Subunit Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Recombinant Protein Vaccines, Virus Like Particle Vaccines, Toxoid Based Protein Vaccines, Polysaccharide Conjugate Vaccines
  • 9.9. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Sub-Segmentation Of Peptide Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Synthetic Peptide Vaccines, Personalized Peptide Vaccines, Multi Epitope Peptide Vaccines, Long Peptide Vaccines
  • 9.10. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Sub-Segmentation Of Other Vaccine Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

10. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Regional And Country Analysis

  • 10.1. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 11.1. Asia-Pacific Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 12.1. China Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 13.1. India Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 14.1. Japan Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 15.1. Australia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 16.1. Indonesia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 17.1. South Korea Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 18.1. Taiwan Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 19.1. South East Asia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 20.1. Western Europe Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 21.1. UK Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 22.1. Germany Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 23.1. France Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 24.1. Italy Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 25.1. Spain Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 26.1. Eastern Europe Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 27.1. Russia Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 28.1. North America Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 29.1. USA Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 30.1. Canada Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 31.1. South America Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 32.1. Brazil Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 33.1. Middle East Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

  • 34.1. Africa Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market, Segmentation By Vaccine Type, Segmentation By Technology or Platform, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Regulatory and Investment Landscape

36. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Competitive Landscape And Company Profiles

  • 36.1. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

37. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Other Major And Innovative Companies

  • Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc

38. Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market

41. Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market High Potential Countries, Segments and Strategies

  • 41.1 Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제